Kiel Laboratories helps clients move through the regulatory process with speed and confidence. With decades of direct experience in pharmaceutical regulatory affairs strategy and filings support, we go beyond basic consulting to truly understand what it takes to get your product approved, whether you’re preparing for a new submission or managing a post-market safety commitment. Our team combines strategic insight, technical understanding, and responsive regulatory strategy consulting services to maximize your product’s potential. Kiel keeps your timeline moving forward with dedicated resources and the ability to meet tight FDA deadlines.
Real-World Regulatory Expertise
The right strategy makes all the difference. Kiel helps you evaluate your options, define a clear regulatory path, and navigate the process without wasting time or budget. With support that spans early planning, submission execution, FDA communication, and post-market compliance, we deliver practical, real-world guidance at every step.
Regulatory Planning & Strategy
From the start, we help you define the most effective and efficient path to approval and design development programs that align with FDA expectations:
- Regulatory pathway assessment, strategy, & gap analysis: Identify the right approval path (NDA, ANDA, 505(b)(2), 351(k), OTC, etc.) and assess what you need to get there
- FDA’s special designation: Apply for orphan status, rare disease, fast track, protocol assessments, or accelerated approval designations with expert support
- Pediatric study plans (PREA compliance): Evaluate when full pediatric studies are required, when waivers can be pursued, and how to navigate the Pediatric Research Equity Act
Regulatory Submission
When you’re ready to submit, we manage the details accurately and efficiently through preparation, submission, and support services. We manage technical writing and compilation for any regulatory filing and ensure submission formats follow required structures with validated eCTD software. The use of AI-enabled tools streamline review and reduce time to filing.
FDA Communication
Effective FDA interactions require precision and clarity. We help you prepare for and respond to every step. Our experience with varied dosage forms and indications helps us anticipate common delays and resolve them faster:
- FDA meeting requests: Support for Type A, B, C, D, and INTERACT, including briefing packages and strategy in line with FDA meeting guidance
- Information request support: Interpret FDA questions and deliver clear, compliant responses accurately and within tight deadlines
Post-Market Regulatory Support
Approval is just the beginning. We help you stay compliant and manage your ongoing regulatory responsibilities. This includes post-marketing requirements and commitments, annual reports, and support for required follow-up research. Whether it’s pre-approval strategy or post-approval compliance, we bring together the capabilities of a top-tier regulatory compliance consulting services partner with the responsiveness of a small, experienced team.
Regulatory Strategy & Filings FAQs
Get answers to common questions about pharmaceutical regulatory strategy, FDA pathways, and submission planning.
There are several FDA regulatory pathways, each designed for different types of drug products:
- New Drug Application (NDA): For innovative drugs with full clinical data demonstrating safety and efficacy
- Abbreviated New Drug Application (ANDA): For generic drugs that demonstrate bioequivalence to a reference listed drug
- 505(b)(2): A hybrid pathway that allows sponsors to rely partly on existing data while providing new studies to support changes (e.g., formulation or indication)
- 351(k): For biosimilars, demonstrating similarity to an approved biologic product
- OTC pathway (Monograph or NDA): For over-the-counter products, depending on whether the product fits within an established OTC monograph or requires a new application
Selecting the right regulatory pathway depends on several factors, including the nature of the active ingredient, the proposed indication, existing data, reference products, and the level of innovation involved. A thorough assessment early in development helps clarify which approval pathway is most appropriate, what studies and data are required, how long the process may take, and the overall cost and risk profile. Aligning on the correct pathway upfront is critical to minimizing risk, avoiding rework, and keeping development timelines and expectations aligned as the program progresses.
Regulatory strategy should be defined as early as possible, ideally during the concept or feasibility stage. Early alignment ensures that development activities, including formulation, analytical testing, and clinical planning, are designed to meet FDA expectations. Defining regulatory strategy too late can lead to gaps in data, additional studies, or delays in submission, making early planning a key factor in maintaining efficient timelines.
Preparing a regulatory submission involves compiling all required technical, clinical, and quality data into a structured format that meets FDA requirements. This includes authoring and organizing documents, data integrity and consistency across sections, and formatting content according to eCTD standards. The process also involves cross-functional coordination to confirm that all components are complete, accurate, and aligned with the chosen regulatory pathway.
Effective preparation for FDA meetings requires clear objectives, well-organized briefing materials, and a strong understanding of the key questions that need to be addressed. Companies should anticipate potential FDA concerns, align internally on messaging, and ensure that supporting data is presented clearly and concisely. Preparation also includes planning for follow-up actions, such as responding to feedback or submitting additional information within tight timelines.
A partner with direct FDA experience brings practical insight into how regulatory expectations are applied in real-world scenarios. This includes understanding common areas of scrutiny, anticipating potential questions, and preparing submissions and responses that align with FDA preferences. Experienced partners can also help streamline FDA interactions, reduce the likelihood of deficiencies or requests for additional information, and improve the overall efficiency of the approval process.
Kiel Laboratories provides end-to-end regulatory support, from early pathway assessment and strategy development through submission preparation, FDA interactions, and post-market. With hands-on experience across a range of dosage forms and regulatory pathways, the team helps clients define clear, efficient paths to approval and navigate complex regulatory requirements with confidence.
By combining strategic insight with execution support, Kiel helps ensure that regulatory activities stay aligned with development goals and timelines.
Unlock Regulatory Strategy Based on Real Experience
Whether you’re mapping your approval pathway or responding to an urgent FDA request, Kiel brings deep expertise in pharmaceutical regulatory affairs strategy and filings support with the responsiveness and foresight to keep your progress on track.